NYU Langone Medical Center
New York, New York – United States
NIH BIOGRAPHICAL SKETCH
NAME: Hu, Kenneth Shung
POSITION TITLE: Associate Professor of Radiation Oncology
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION DEGREE
FIELD OF STUDY
University of California, Los Angeles B.S 06/1988 Molecular Cellular Developmental Biology
Harvard Medical School—Massachusetts Institute of Technology, Boston
M.D. 06/1994 Medicine
Cedars-Sinai Medical Center, Los Angeles Internship 06/1995 Internship, Medicine
Memorial Sloan-Kettering Cancer Center, New York Residency 06/1998 Radiation Oncology
Beth Israel Medical Center, New York Fellowship 06/1999 Brachytherapy
A. Personal Statement
I have dedicated my career to the practice, research and teaching of head and neck radiation oncology, a highly specialized area of expertise for a tumor site that is the 5th most common cause of cancer globally and 10th in the U.S. I am recognized as both a national and international expert in head and neck oncology.
I have been involved in teaching at the institutional, city, national and international levels and have mentored residents/fellows over the past 15 years. Many have proceeded to highly successful careers in both academic and private practice settings. I have been invited to give lectures in the city by the NY Roentgen Society,Treatment of Head and Neck Cancer (THANC) Foundation, as well as through visiting professorships at Columbia, Cornell, Mount Sinai and Memorial Sloan Kettering Cancer Center. Nationally, I have served as faculty for the annual and spring refresher courses, chaired specialty meetings in image guided/adaptive radiation therapy, led the annual econtouring training course as program director, chaired the head and neck scientific abstracts review committee, and served as director of the global health education committee of our professional society, American Society of Therapeutic Radiation Oncology. I’ve also been highly involved in the American Board of Radiology as a head and neck specialty examiner and question/case contributor to both the oral and written board exams required for board certification and maintenance of certification. I served as the program director and speaker for the Biannual International Society for Intraoperative Radiation Therapy and have been invited as faculty to the International Atomic and Energy Agency 2nd symposium on advances in radiation oncology.
My scientific focus has been on clinical/translational research developing novel therapeutic approaches such as 1) incorporating new radiation treatment targeting of disease such as a) expanding the use of unilateral radiation therapy in lateralized head and neck cancers by defining new criteria to select patients b) pioneering the use of oropharynx-directed treatment of unknown squamous cell carcinoma primaries, 2) developing intraoperative radiation therapy techniques in a multidisciplinary salvage regimen for recurrent head and neck cancer 3) establishing multidisciplinary treatment algorithms for rare head and neck diseases such as paragangliomas and 4) integrating brachytherapy for tongue preservation protocols. The majority of the research is investigator-initiated with funding from university and industry settings. I have also participated extensively in cooperative group protocols primarily through the Radiation Therapy Oncology Group and NRG.
Having joined the group at NYU over 3 years ago, I have developed an innovative treatment approach for favorable-risk oropharynx cancer patients investigating the potential for treatment de-escalation in tumors demonstrating rapid shrinkage mid-treatment. Oropharynx cancer is one of the most common head and neck cancers with a rapidly increasing incidence worldwide. The biology of the tumor has evolved over the past decade from a highly aggressive one related to smoking/drinking to one that is highly curable linked to human papilloma virus and minimal tobacco use. The prognosis for such tumors has changed such that there is about a 30% improvement in survival in those that are HPV+ compared to those that are related primarily to tobacco. This subset of favorable risk represents about 40% of all oropharynx cancer patients. Given the favorable outcomes, research is needed to deescalate treatment as well as follow-up and lower the toxicity/cost burden for patients and healthcare systems. In addition many of the HPV+ patients are about a decade younger than those with non-HPV related head and neck cancers such that supportive/preventive care to preserve speech and swallowing, dental and psychosocial health become paramount. Finding the right balance of effective treatment versus minimizing toxicity offers a major research opportunity which is an area of active interest with our specialized multi-disciplinary group.
Positions and Employment
1999- 2015Attending, Department of Radiation Oncology
Beth Israel Medical Center, NY, NY
1999 - 2015Attending
New York Eye and Infirmary, NY, NY
1999- 2008Assistant Professor of Radiation Oncology
Albert Einstein College of Medicine, Bronx, NY
2001-2015Clinical Asst. Professor of Radiation Oncology
SUNY Downstate Medical Center, Brooklyn, NY
2002-2015 Director of Radiation Oncology Programs
New York Eye and Ear Infirmary, NY, NY
2007-2015 Co-Director of the Head and Neck Institute,
Beth Israel Medical Center, NY, NY
2009 – 2014Associate Professor of Radiation Oncology
Albert Einstein College of Medicine, Bronx, NY
2014 – 2015 Associate Professor of Radiation Oncology
Mt. Sinai Icahn School of Medicine, NY, NY
2015-present Associate Professor of Radiation Oncology
New York University Medical School, NY, NY
2015-present Co-Director of the NYU Head and Neck Center
Perlmutter Cancer Center, NYU Langone Medical Center, NY, NY
Other Experience and Professional Memberships
2001-2002 New York Roentgen Society, Chairman 2002, Vice-Chairman 2001
2001-2004American Society for Therapeutic Radiation Oncology Annual Course Faculty ,
“Strategies to Minimize Toxicity from Head and Neck Radiation”
2002-presentNew York Head and Neck Society, Membership 2014-2105, Treasurer 2013, 2016
Executive Committee Member 2002-present
2005-2014International Society for Intraoperative Radiation Therapy
Scientific Program Chair, 4th Meeting, Miami, Fla. Mar 17-19, 2005.
2008-2016American Society of Therapeutic Radiation Oncology Global Health Education Subcommittee Chair 2014-2016, Vice Chair 2012-2013, Member, 2008-2012
2009-2011American Society of Therapeutic Radiation Oncology Scientific Chair of Abstract Review for Head and Neck Section
2010-2012American Society of Therapeutic Radiation Oncology E-contouring Program, Course Director
2012-presentAmerican Board of Radiology Head and Neck Written Exam Writer for Certification and Maintenance of Certification
2002, 2005-6American Board of Radiology Oral Examiner and Oral Exam Writer in Head and Neck Section, 2013-present Radiation Oncology Certification
1991. Irving London Research Fellowship, Harvard Medical School, Boston, MA
1991-1992Howard Hughes Medical Institute Medical Student Research Fellowship
1995Berlex Oncology Foundation Award: Epidemiology and Clinical Trial Design
2000ASTRO/ESTRO Fellowship Exchange Travel Award, Institut Gustav Roussy, Paris, FR
2014-16Castle Connolly Best Doctor in Radiation Oncology, New York
C. Contribution to Science:
My contribution can broadly be classified into 4 major areas as follows:
1. Precision targeting of head and neck cancer patients. With the development of highly conformal radiation therapy treatment systems as well image guidance using functional imaging and on-board imaging, the ability to conform dose to areas at risk for tumor involvement requires considerable judgment and experience. The precise targeting offers the potential for less acute/chronic toxicity with greater normal tissue sparing but increases the risk of geographically missing the tumor. In collaboration with my colleague and former chairman Louis Harrison with whom I have partnered a large head and neck cancer practice for over 15 years, we initiated a prospective phase II trial demonstrating that unilateral radiation can safely be expanded to treat advanced stage oropharynx cancers including those that are human papilloma virus related which represents one of the most common head and neck cancers currently in developed countries and a rapidly growing subset of patients globally. Such an approach was historically restricted to patients with small tumors with minimal nodal disease. The sparing of contralateral organs ensures the high likelihood for maintaining normal swallowing, salivary and dental functions. Another example of precision targeting is in the treatment of squamous cell carcinoma of the head and neck with unknown primary. Instead of treating the entire aerodigestive tract from the nasopharynx to the hypopharynx, we investigated a unique long-term experience limiting elective radiation treatment to the oropharynx, the most common area for an emergence of primary with very low rates of out of field failure allowing major sparing of the voice box and swallowing muscles. A third example is a contouring atlas our group developed to cover pathways of perineural spread for head and neck cancers. The atlas was adopted by the Radiation Therapy Oncology Group and is posted on its website.
1. Hu KS, et al. Low Rates of Contralateral Neck Failure in Unilaterally Treated Oropharynx and Oral Cavity Squamous Cell Carcinoma with Prospectively Defined Criteria of Lateralization. Head and Neck. 2017; 39 (8):1647-54
2. Hu KS, Mourad WF, Gamez ME, Lin W, Jacobson A, Persky MS, Gamez ME, Urken M, Culliney BE, Li Z, Tran T, Schantz S, Chadha J, Harrison LB. Five-year outcomes of an oropharynx-directed treatment approach for unknown primary of the head and neck. Oral Oncology. 2017;70:14-22
3. Mourad WF, Young BM, Young R, Blakaj DM, Orhi N, Shourbaji RA, Manolidis S, Gámez M, Kumar M, Khorsandi A, Khan MA, Shasha D, Blakaj A, Glanzman J, Garg MK, Hu KS, Kalnicki S, Harrison LB. Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. Oral Oncol. 2013;49(9):956-63.
2. The application of brachytherapy approaches in the treatment of tongue cancers for organ preservation as well as use in the salvage of previously irradiated locoregionally recurrent head and neck cancers. Brachytherapy permits highly conformal radiation therapy to the tumor site by implanting radiation isotopes directly into the tumor, bypassing normal tissue that would be exposed with external beam radiation technique such as intensity modulated radiation or proton therapy. These approaches simultaneously allow dose-escalation to the tumor bed while decreasing dose to surrounding tissue. In the newly diagnosed patient, this permits reduction of external beam radiation doses to the salivary glands, dental structures and swallowing muscles. In the recurrent setting, brachytherapy can safely delivery oncologically meaningful doses in patients previously irradiated and minimize the risk of severe long term complications of retreatment such as carotid artery bleed, mandibular necrosis and fistula formation. Our intraoperative radiation experience for salvage of recurrent head and neck cancer is one of the largest in both the U.S. and globally.
1. Debenham BJ, Hu KS, Harrison LB. Present status and future directions of intraoperative radiotherapy. Lancet Oncol. 2013 Oct;14(11):e457-64.
2. Scala LM, Hu K, Urken ML, Jacobson AS, Persky MS, Tran TN, Smith ML, Schantz S, Harrison LB. Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer. Head Neck. 2013 Apr;35(4):485-92.
3. Hu K, Harrison LB. Point: brachytherapy versus intensity-modulated radiation therapy in the management of base of tongue cancers. Brachytherapy. 2005;4(1):1-4; discussion 7-8.
4. Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Semin Oncol. 2003 Dec;30(6 Suppl 18):40-8.
3. Development of a multi-disciplinary algorithm to treat paragangliomas of the head and neck. This is a rare tumor that for many years was treated with surgical resection, a highly effective treatment yet one which is associated with high rates of iatrogenic cranial neuropathy. We published an initial proposal and then published our ten-year experience demonstrating that radiation therapy is the treatment of choice for skull base paragangliomas while surgery is best for carotid body tumors.
1. Hu K, Persky MS. Treatment of Head and Neck Paragangliomas. Cancer Control. 2016 Jul;23(3):228-41.
2. Hu K, Persky MS. The multidisciplinary management of paragangliomas of the head and neck, Part 2. Oncology (Williston Park). 2003 Aug;17(8):1143-53; discussion 1154, 1158, 1161.
3. Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck, Part 1. Oncology (Williston Park). 2003 Jul;17(7):983-93.
4. Global health education. I have chaired the ASTRO global health education subcommittee over the past 2 years and served as vice-chair the preceding 2 years. I recognize that an important approach to bridging knowledge gaps is to integrate information and communication tools (ICT) to allow hands-on, sustainable learning. As Director of the ASTRO contouring educational program and serving as a head and neck contouring instructor for 5 years which each year taught approximately 800 participants state-of-the art contouring guidelines for head and neck, prostate, gynecologic, lung, lymphoma, breast and gastrointestinal tumors, I understood the value of a web-based teaching tool. We switched our outreach model from traditional visiting professorships where on-site lectures and question/answer sessions were delivered over a several day trip to one in which we recruit domestic and international ambassadors to become proficient in using ICT to enhance their educational mission. We are currently working to develop an interactive webinar to lead case discussion interfacing experts with practitioners who present their cases in web-based formats.
1. Dad L, Royce TJ, Morris Z, Moran M, Pawlicki T, Khuntia D, Hardenbergh P, Cummings B, Mayr N, Hu KS. Bridging innovation and outreach to overcome global gaps in Radiation Oncology through Information and Communication Tools (ICTs), Trainee Advancement, Engaging Industry, Attention to Ethical Challenges, and Political Advocacy. Semin Radiat Oncol. 2017 Apr;27(2):98-108
2. Mailhot, R; Ishaq, O; Inaya, A; Rene, L; Amendola, B; Hu, K. A novel, pilot curriculum for international education of lymphoma management employing e-contouring. Journal of Global Oncology. In press.
3. ASTRO E-contouring Program Director 2010-2012, Head and Neck contouring instructor, 2008-2010
Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/sites/myncbi/1L76iYOZIhhka/bibliography/50845422/public/?sort=date&direction=ascending
Tuesday, November 5
8:30 AM – 12:30 PM